ArticleJCO oncology practice2026
Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.
Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective.Risk management and healthcare policy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWith more patients with metastatic renal cell carcinoma (mRCC) receiving immuno-oncology (IO) and vascular endothelial growth factor (VEGF)-targeted therapies, understanding treatment patterns and outcomes following these therapies is essential. To describe patient characteristics, treatment patterns, and health care resource use (HCRU) among patients with mRCC with previous receipt of IO- and VEGF-based therapies. PATIENTS AND
methodsThis retrospective cohort study identified adults in Optum's Clinformatics Data Mart Database who were diagnosed with mRCC from August 2015 through July 2022 and received subsequent therapies after IO- and VEGF-based therapies. Patients were classified by the first line of treatment that they received after exposure to IO- and VEGF-based therapies. Outcomes included treatment patterns (time on treatment [ToT], time to next treatment [TTNT]), HCRU, and costs.
resultsWe identified 664 patients with mRCC with previous receipt of IO- and VEGF-based therapies (2L cohort: 186 patients, 3L cohort: 429 patients, 4L cohort: 49 patients). Cohorts were similar in terms of age (median 66-69 years), gender (72.0%-75.5% male), and race (63.3%-68.8% White). The median ToT was 4.4, 5.0, and 5.6 months and the median TTNT was 10.7, 11.7, and 9.5 months for 2L, 3L, and 4L cohorts, respectively. The HCRU increased by progressive lines of therapy (LOT), including inpatient hospital admissions (22.0%, 27.7%, and 32.7%) and emergency visits (26.9%, 30.3%, and 32.7%). The total cost across cohorts was $23,605 per patient per month.
conclusionsOur study provides a comprehensive evaluation of clinical and economic impacts of therapies administered to patients with mRCC after IO- and VEGF-based therapies. It highlights a need for novel, cost-effective treatments and studies examining patient out-of-pocket costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.